Immunosuppressive Drugs for Kidney Transplantation
Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reve...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-12, Vol.351 (26), p.2715-2729 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2729 |
|---|---|
| container_issue | 26 |
| container_start_page | 2715 |
| container_title | The New England journal of medicine |
| container_volume | 351 |
| creator | Halloran, Philip F |
| description | Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
The central issue in organ transplantation remains suppression of allograft rejection. Thus, development of immunosuppressive drugs is the key to successful allograft function. Immunosuppressive agents are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review focuses on agents that are either approved or in phase 2 or phase 3 trials in kidney transplantation, but many issues covered here are applicable to all organ transplantation. I begin with a model of the alloimmune response to illustrate how these medications act.
Three-Signal Model of Alloimmune Responses
Alloimmune responses involve both naive and . . . |
| doi_str_mv | 10.1056/NEJMra033540 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67190056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>771781691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-220245c9e6048a38978001584ccdbe07d76ed4bdb9a4fefab0df4a629ae32bfe3</originalsourceid><addsrcrecordid>eNqF0ElLw0AUB_BBFFurN88SRD0ZfbMmc5Ra16qXeg6TyURSsjmTCP32TmmgIoLv8i4_3vJH6BjDFQYurl9nTy9WAaWcwQ4aY05pyBiIXTQGIHHIIklH6MC5JfjCTO6jEeYCCwJijMhjVfV14_q2tca54ssEt7b_cEHe2OC5yGqzChZW1a4tVd2prmjqQ7SXq9KZo6FP0PvdbDF9COdv94_Tm3moWRx3ISFAGNfSCGCxorGMYr-ex0zrLDUQZZEwGUuzVCqWm1ylkOVMCSKVoSTNDZ2gi83c1jafvXFdUhVOm9IfYpreJSLCEnwC_0IccR5LIB6e_oLLpre1fyIhhErq716jyw3StnHOmjxpbVEpu0owJOvEk5-Je34yzOzTymRbPETswfkAlNOqzH2YunBbJ6jgEWDvzjauqlxSm2X1975vpEiS7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223934882</pqid></control><display><type>article</type><title>Immunosuppressive Drugs for Kidney Transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Halloran, Philip F</creator><creatorcontrib>Halloran, Philip F</creatorcontrib><description>Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
The central issue in organ transplantation remains suppression of allograft rejection. Thus, development of immunosuppressive drugs is the key to successful allograft function. Immunosuppressive agents are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review focuses on agents that are either approved or in phase 2 or phase 3 trials in kidney transplantation, but many issues covered here are applicable to all organ transplantation. I begin with a model of the alloimmune response to illustrate how these medications act.
Three-Signal Model of Alloimmune Responses
Alloimmune responses involve both naive and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMra033540</identifier><identifier>PMID: 15616206</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adaptation ; Antibodies, Monoclonal - therapeutic use ; Antigens, CD - immunology ; Biological and medical sciences ; Clinical Protocols ; Endothelium ; General aspects ; Graft Rejection - immunology ; Graft Rejection - prevention & control ; Humans ; Immune system ; Immunology ; Immunosuppressive Agents - classification ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Kidney Failure, Chronic - surgery ; Kidney Transplantation - adverse effects ; Kidney Transplantation - immunology ; Lymphocytes ; Medical sciences ; Proteins ; Signal transduction ; T-Lymphocytes - immunology ; Transplantation Immunology - drug effects</subject><ispartof>The New England journal of medicine, 2004-12, Vol.351 (26), p.2715-2729</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-220245c9e6048a38978001584ccdbe07d76ed4bdb9a4fefab0df4a629ae32bfe3</citedby><cites>FETCH-LOGICAL-c488t-220245c9e6048a38978001584ccdbe07d76ed4bdb9a4fefab0df4a629ae32bfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMra033540$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223934882?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16365701$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15616206$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halloran, Philip F</creatorcontrib><title>Immunosuppressive Drugs for Kidney Transplantation</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
The central issue in organ transplantation remains suppression of allograft rejection. Thus, development of immunosuppressive drugs is the key to successful allograft function. Immunosuppressive agents are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review focuses on agents that are either approved or in phase 2 or phase 3 trials in kidney transplantation, but many issues covered here are applicable to all organ transplantation. I begin with a model of the alloimmune response to illustrate how these medications act.
Three-Signal Model of Alloimmune Responses
Alloimmune responses involve both naive and . . .</description><subject>Adaptation</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens, CD - immunology</subject><subject>Biological and medical sciences</subject><subject>Clinical Protocols</subject><subject>Endothelium</subject><subject>General aspects</subject><subject>Graft Rejection - immunology</subject><subject>Graft Rejection - prevention & control</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Immunosuppressive Agents - classification</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - immunology</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>T-Lymphocytes - immunology</subject><subject>Transplantation Immunology - drug effects</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0ElLw0AUB_BBFFurN88SRD0ZfbMmc5Ra16qXeg6TyURSsjmTCP32TmmgIoLv8i4_3vJH6BjDFQYurl9nTy9WAaWcwQ4aY05pyBiIXTQGIHHIIklH6MC5JfjCTO6jEeYCCwJijMhjVfV14_q2tca54ssEt7b_cEHe2OC5yGqzChZW1a4tVd2prmjqQ7SXq9KZo6FP0PvdbDF9COdv94_Tm3moWRx3ISFAGNfSCGCxorGMYr-ex0zrLDUQZZEwGUuzVCqWm1ylkOVMCSKVoSTNDZ2gi83c1jafvXFdUhVOm9IfYpreJSLCEnwC_0IccR5LIB6e_oLLpre1fyIhhErq716jyw3StnHOmjxpbVEpu0owJOvEk5-Je34yzOzTymRbPETswfkAlNOqzH2YunBbJ6jgEWDvzjauqlxSm2X1975vpEiS7A</recordid><startdate>20041223</startdate><enddate>20041223</enddate><creator>Halloran, Philip F</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20041223</creationdate><title>Immunosuppressive Drugs for Kidney Transplantation</title><author>Halloran, Philip F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-220245c9e6048a38978001584ccdbe07d76ed4bdb9a4fefab0df4a629ae32bfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adaptation</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens, CD - immunology</topic><topic>Biological and medical sciences</topic><topic>Clinical Protocols</topic><topic>Endothelium</topic><topic>General aspects</topic><topic>Graft Rejection - immunology</topic><topic>Graft Rejection - prevention & control</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Immunosuppressive Agents - classification</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - immunology</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>T-Lymphocytes - immunology</topic><topic>Transplantation Immunology - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halloran, Philip F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halloran, Philip F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunosuppressive Drugs for Kidney Transplantation</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-12-23</date><risdate>2004</risdate><volume>351</volume><issue>26</issue><spage>2715</spage><epage>2729</epage><pages>2715-2729</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
The central issue in organ transplantation remains suppression of allograft rejection. Thus, development of immunosuppressive drugs is the key to successful allograft function. Immunosuppressive agents are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review focuses on agents that are either approved or in phase 2 or phase 3 trials in kidney transplantation, but many issues covered here are applicable to all organ transplantation. I begin with a model of the alloimmune response to illustrate how these medications act.
Three-Signal Model of Alloimmune Responses
Alloimmune responses involve both naive and . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>15616206</pmid><doi>10.1056/NEJMra033540</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-12, Vol.351 (26), p.2715-2729 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67190056 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adaptation Antibodies, Monoclonal - therapeutic use Antigens, CD - immunology Biological and medical sciences Clinical Protocols Endothelium General aspects Graft Rejection - immunology Graft Rejection - prevention & control Humans Immune system Immunology Immunosuppressive Agents - classification Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Kidney Failure, Chronic - surgery Kidney Transplantation - adverse effects Kidney Transplantation - immunology Lymphocytes Medical sciences Proteins Signal transduction T-Lymphocytes - immunology Transplantation Immunology - drug effects |
| title | Immunosuppressive Drugs for Kidney Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A17%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunosuppressive%20Drugs%20for%20Kidney%20Transplantation&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Halloran,%20Philip%20F&rft.date=2004-12-23&rft.volume=351&rft.issue=26&rft.spage=2715&rft.epage=2729&rft.pages=2715-2729&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMra033540&rft_dat=%3Cproquest_cross%3E771781691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223934882&rft_id=info:pmid/15616206&rfr_iscdi=true |